Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
Zacks News
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
by Zacks Equity Research
Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
by Zacks Equity Research
Immunovant (IMVT) announces encouraging initial results from its early-stage study of IMVT-1402. The stock of the company rallies 97%.
Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal
by Zacks Equity Research
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
Repligen (RGEN) to Acquire Fluid Management Company Metenova
by Zacks Equity Research
Repligen (RGEN) is set to acquire a Swedish company, Metenova, which focuses on manufacturing magnetic mixers for pharmaceutical and biotechnology applications.
AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
by Zacks Equity Research
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
Novo Nordisk (NVO), Valo Ink Deal to Develop Heart Disease Drugs
by Zacks Equity Research
Novo Nordisk (NVO) collaborates with Valo Health to discover and develop novel treatments for cardiometabolic diseases using Valo's proprietary drug development platform.
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
by Zacks Equity Research
Biophytis (BPTS) gains on signing a partnership with Skyepharma, for the production of regulatory batches of its lead candidate, Sarconeos (BIO101).
AstraZeneca's (AZN) Dato-DXd Meets Goal in Breast Cancer Study
by Zacks Equity Research
AstraZeneca (AZN) announces positive results from the late-stage study evaluating its antibody-drug conjugate, Dato-DXd, in pre-treated patients with HR+/HER2- metastatic breast cancer.
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
by Zacks Equity Research
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
by Zacks Equity Research
Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.
Relmada (RLMD) Up on Positive Data for Anti-Depressant Candidate
by Zacks Equity Research
Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with major depressive disorder.
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
by Zacks Equity Research
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
by Zacks Equity Research
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
by Zacks Equity Research
Atara (ATRA) rises 11% on an update regarding the regulatory pathway for the company's lead product candidate, tab-cel, in the treatment of a rare, deadly and hematologic malignancy.
Merck (MRK) Keytruda Cervical Cancer sBLA Gets FDA Priority Tag
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) sBLA seeking expanded use of Keytruda for an earlier stage of cervical cancer disease.
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
Marinus (MRNS) Up 20% on Financial and Pipeline Updates
by Zacks Equity Research
Marinus' (MRNS) shares rise as it provides revenue and cash guidance for third-quarter 2023. The company also updates on the progress of its pipeline candidates targeting major central nervous system disorders.
Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
by Zacks Equity Research
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Strength Seen in Profound Medical (PROF): Can Its 19.5% Jump Turn into More Strength?
by Zacks Equity Research
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up
by Zacks Equity Research
Orchard's (ORTX) regulatory filing for OTL-200, in the treatment of pediatric patients suffering from metachromatic leukodystrophy, gets FDA acceptance under Priority Review. The stock rises 16%.
Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod
by Zacks Equity Research
Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.
Here's Why You Should Invest in Alpine (ALPN) Stock Now
by Zacks Equity Research
Alpine (ALPN) plans to begin a broad and accelerated development program for povetacicept across multiple indications in 2024.
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
by Zacks Equity Research
Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.
GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia
by Zacks Equity Research
GSK's Ojjaara (momelotinib) is the first and the only drug approved to treat myelofibrosis patients with anemia in the United States.